Exclusive: Regulators investigate after patients harmed by unlicensed treatment from firm paid millions by NHS
A cancer patient has died and three others have been hospitalised after they were administered unlicensed versions of chemotherapy by Sciensus, a private company paid millions by the NHS to provide essential medication, the Guardian can reveal.
Three health regulators have launched inquiries into the incident, according to people familiar with the matter. It was caused by an issue at the firm’s medicines manufacturing unit.
